Omega-3 Fatty Acids for High Cholesterol (Dyslipidemia)

This pairing is one of the most widely misunderstood in supplementation. Omega-3 is bought by large numbers of people to lower their cholesterol, and that is not what it does. The dose-dependent, well-replicated effect of EPA and DHA is on triglycerides — reductions of roughly 20-30% at 4 g daily, and around 10-15% at 2 g. The effect on LDL cholesterol is negligible, and at high doses DHA in particular can raise LDL modestly. So the question is not whether omega-3 lowers cholesterol, but which lipid problem you actually have. If your triglycerides are above 1.7 mmol/L, and especially above 5.6 mmol/L where pancreatitis risk enters the picture, prescription-strength omega-3 is a legitimate and guideline-supported intervention. If your problem is elevated LDL or apolipoprotein B, omega-3 is the wrong tool and a statin is the right one. The outcomes picture is separate again and genuinely contested. REDUCE-IT found a 25% reduction in cardiovascular events with 4 g of icosapent ethyl, a purified EPA product, in high-risk patients on statins. STRENGTH, using a mixed EPA/DHA formulation at the same dose, found no benefit. The most likely explanations are a difference between EPA alone and EPA plus DHA, or the mineral oil placebo used in REDUCE-IT. Over-the-counter fish oil at 1 g daily has repeatedly failed to reduce events.

The triglyceride-lowering effect works from both ends of the pathway. EPA and DHA reduce hepatic synthesis of triglycerides by inhibiting diacylglycerol acyltransferase and by suppressing lipogenic gene transcription through PPAR-alpha activation and SREBP-1c downregulation. Simultaneously they increase fatty acid beta-oxidation in the liver, diverting substrate away from triglyceride assembly, and they enhance lipoprotein lipase activity, which speeds clearance of triglyceride-rich particles from the circulation. The net result is fewer VLDL particles secreted and faster clearance of those that are. Why LDL does not fall follows from the same biology. Faster conversion of VLDL to LDL means more LDL particles are produced from the reduced VLDL pool, offsetting any gain. DHA has a larger LDL-raising effect than EPA, which is part of the argument for purified EPA formulations. The proposed cardiovascular mechanisms extend beyond lipids: incorporation of EPA into membrane phospholipids improves membrane fluidity, EPA is the substrate for resolvins and other specialised pro-resolving mediators that actively terminate inflammation, and there are measurable effects on platelet aggregation, endothelial function and arrhythmia threshold.

The triglyceride effect is not in doubt. Dose-response meta-analyses consistently show reductions of roughly 20-30% at 4 g daily of combined EPA and DHA, with a clear dose gradient below that. The same analyses show LDL either unchanged or slightly increased, with the increase driven mainly by DHA. The outcomes literature is where the disagreement lies. REDUCE-IT randomized 8,179 statin-treated patients with elevated triglycerides to 4 g of icosapent ethyl or placebo and reported a 25% relative reduction in major cardiovascular events. STRENGTH randomized 13,078 comparable patients to 4 g of a mixed EPA/DHA carboxylic acid formulation and was stopped early for futility. Two well-conducted trials, the same dose, opposite results. Two explanations dominate. The first is that purified EPA differs materially from EPA plus DHA — EPA achieves higher plasma levels in REDUCE-IT and DHA may offset benefit. The second is the placebo: REDUCE-IT used mineral oil, and the placebo group showed rises in LDL and hs-CRP, raising the possibility that part of the apparent benefit reflects harm in the comparator. Separately, low-dose fish oil for primary prevention has been repeatedly negative. VITAL, with 25,871 participants on 840 mg daily, found no reduction in the primary composite endpoint. ASCEND, in 15,480 people with diabetes on 840 mg, likewise found no benefit. The practical conclusion is that 1 g of over-the-counter fish oil is not a cardiovascular drug.

Omega-3 reduces platelet aggregation, and the theoretical bleeding concern is frequently raised. In practice, trials including patients on aspirin and clopidogrel have not shown clinically significant increases in major bleeding at doses up to 4 g. Guidance has moved away from routinely stopping fish oil before surgery. That said, tell your surgeon or anticoagulation clinic what you are taking and let them make the call, particularly on warfarin where INR should be monitored after any change.